EE62 Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed By Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer (ETNBC) in France
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.334
https://www.valueinhealthjournal.com/article/S1098-3015(23)03464-2/fulltext
Title :
EE62 Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed By Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer (ETNBC) in France
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03464-2&doi=10.1016/j.jval.2023.09.334
First page :
Section Title :
Open access? :
No
Section Order :
12358